Caredx Inc(CDNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 24.14 | EPS (ttm) | 2.07 | Insider Own | 9.05% | Shs Outstand | 51.5M | Perf Week | 0.97% |
| Market Cap | 2.59B | Forward P/E | 37.71 | EPS next Y | 10.31% | Insider Trans | -6.96% | Shs Float | 47.0M | Perf Month | 6.03% |
| Enterprise Value | 2.24B | PEG | 0.8 | EPS next Q | 0.25 | Inst Own | 100.15% | Short Float | 12.31% | Perf Quarter | 113.47% |
| Income | 0.11B | P/S | 5.66 | EPS this Y | 107.55% | Inst Trans | 0.91% | Short Ratio | 5.07 | Perf Half Y | 192.01% |
| Sales | 0.46B | P/B | 6.06 | EPS next 5Y | 46.93% | ROA | 22.72% | Short Interest | 5.79M | Perf YTD | 165.82% |
| Book/sh | 8.27 | P/C | 6.93 | EPS past 3/5Y | 34.67% 0.09% | ROE | 29.49% | 52W High | -6.69% ($53.67) | Perf Year | 275.69% |
| Cash/sh | 7.22 | P/FCF | 30.59 | Sales past 3/5Y | 5.68% 14.59% | ROIC | 25.3% | 52W Low | 281.72% ($13.12) | Perf 3Y | 512.97% |
| Dividend Est. | - | EV/EBITDA | 124.46 | EPS Y/Y TTM | 90.73% | Gross Margin | 70.11% | Volatility(W/M) | 4.3% 4.7% | Perf 5Y | -27.91% |
| Dividend TTM | - | EV/Sales | 4.88 | Sales Y/Y TTM | 34.41% | Oper. Margin | -0.4% | ATR (14) | 2.36 | Perf 10Y | 979.31% |
| Dividend Ex-Date | - | Quick Ratio | 4.51 | EPS Q/Q | 1412.42% | Profit Margin | 24.23% | RSI (14) | 61.87 | Recom | 1.75 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.58 | Sales Q/Q | 52.23% | SMA20 | 2.35% ($48.93) | Beta | 2.42 | Target Price | $54.14 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/7/30 | SMA50 | 19.27% ($41.99) | Rel Volume | 1.41 | Prev Close | $50.03 |
| Employees | 765 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 59.41% 15.69% | SMA200 | 95.79% ($25.58) | Avg Volume(3M) | 1.14M | Price | $50.08 |
| IPO | 2014/7/17 | Option/Short | Yes/Yes | Trades | 15208 | Volume | 1,605,556 | Change | 0.1% |
Company
CDNA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a US diagnostics company that develops and supplies precision diagnostic solutions for long-term transplant patients. Built on technology that uses non-invasive blood tests to detect the risk of organ rejection early, the company has established a differentiated position in managing transplant patients, including kidney and heart recipients.
Over the past 1 year, on the higher side
7% below its 1-year high.
CDNA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +107.5% this year.
Tap to view numbers
The price looks about right
Trading at 24.1 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +513.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 100.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ARKG 0.03%
PBE 0.03%
HTEC 0.02%
GNOM 0.01%
HELX 0.01%It ranks #4 in the industry
Based on market cap of $3B.
CDNA $3B PER 24.1
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is CDNA?
CDNA belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CDNA?
The market cap of CDNA is approximately $2.6B, ranking 1,900 within its sector.
What is the P/E ratio of CDNA?
CDNA has a P/E ratio of approximately 24.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CDNA?
CDNA has recorded a 52-week high of $53.67 and a low of $13.12.
